

The Prevalence and Prognosis of Resistant Hypertension

PLoS ONE

9, e114958

DOI: [10.1371/journal.pone.0114958](https://doi.org/10.1371/journal.pone.0114958)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. <i>Kidney International</i> , 2015, 88, 622-632.	5.2	146
2	Fisetin protects H9c2 cardiomyoblast cells against H ₂ O ₂ -induced apoptosis through Akt and ERK1/2 signaling pathways. <i>Molecular and Cellular Toxicology</i> , 2018, 14, 183-192.	1.7	2
3	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018, 72, e53-e90.	2.7	629
4	Heart Failure and Frailty in the Community-Living Elderly Population: What the UFO Study Will Tell Us. <i>Frontiers in Physiology</i> , 2018, 9, 347.	2.8	5
5	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (<scp>AMBER</scp>): results in the preâ€specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1462-1471.	7.1	27
6	Heart Failure with Preserved Ejection Fractionâ€”a Concise Review. <i>Current Cardiology Reports</i> , 2020, 22, 82.	2.9	40
7	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. <i>Cardiology and Therapy</i> , 2021, 10, 9-25.	2.6	1
8	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. <i>European Heart Journal</i> , 2021, 42, 3753-3755.	2.2	9
9	Sacubitrilâ€valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	2.2	74
10	Resistance to antihypertensive treatment and longâ€term risk: The Atherosclerosis Risk in Communities study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1887-1896.	2.0	7
11	Ïlinical and anamnestic features and their prognostic value in assessment of treatment efficiency of arterial hypertension with comorbidity. <i>Patologiya</i> , 2018, .	0.1	2
13	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heartâ€Failure Phenotypes in the Swedishâ€HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	4.1	5
14	Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. <i>Cardiac Failure Review</i> , 0, 8, .	3.0	12
15	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction In Patients With Resistant Hypertension and Type 2 Diabetes Mellitus. <i>Kardiologiya</i> , 2022, 62, 11-18.	0.7	0
16	What is resistant arterial hypertension?. <i>Blood Pressure</i> , 2023, 32, .	1.5	10
17	Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension. <i>Hypertension Research</i> , 2023, 46, 1727-1737.	2.7	7
19	Experience of sacubitril/valsartan therapy in hypertension. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3636.	1.4	0
20	Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. <i>Circulation</i> , 0, , .	1.6	1

#	ARTICLE	IF	CITATIONS
21	Resistant Hypertension and Related Outcomes in a Cohort of Patients with Cardiorenal Multimorbidity Hospitalized in an Internal Medicine Ward. High Blood Pressure and Cardiovascular Prevention, O, , .	2.2	0